A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061
| Autor: | Ryan J. Sullivan, Ronald T. Mitsuyasu, Mary Cianfrocca, Richard F. Little, Lee Ratner, S. P. Ivy, Page C. Moore, John F. Gerecitano, Bruce J. Dezube, John F. Deeken, Michelle A. Rudek, David H. Henry, David M. Aboulafia, Kimberly Mosby, Melinda Tibbals |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pathology Epidemiology medicine.drug_class medicine.medical_treatment lcsh:RC254-282 Tyrosine-kinase inhibitor lcsh:Infectious and parasitic diseases Pharmacokinetics Internal medicine Medicine lcsh:RC109-216 Dosing Chemotherapy AIDS Malignancy Consortium business.industry Sunitinib Cancer lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Infectious Diseases Hiv patients Oral Presentation business medicine.drug |
| Zdroj: | Infectious Agents and Cancer, Vol 7, Iss Suppl 1, p O15 (2012) Infectious Agents and Cancer |
| ISSN: | 1750-9378 |
| Popis: | Background In developed counties the rates of non-AIDS defining cancers (NADCs) now exceed those of AIDS-defining cancers in HIV-positive patients. Drug-drug interactions between HAART and chemotherapy may complicate the treatment of patients with NADCs. In order to determine the proper dosing of new targeted chemotherapies in patients with NADCs who are also on HAART, the AMC is performing a series of phase I/pharmacokinetic (PK) studies to determine the proper dosing of these agents in HIV+ cancer patients. We present the results of the first such study which investigated sunitinib, an oral multiple tyrosine kinase inhibitor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink